Adaptimmune Therapeutics Cash from Investing (TTM) Insights

Adaptimmune Therapeutics PLC (ADAP)

0.8984 -0.09 (-8.98%) USD | NASDAQ | Apr 18, 16:00

0.8901 -0.01 (-0.92%) After-Hours: 05:58

Cash from Investing (TTM) Chart

Historical Cash from Investing (TTM) Data

View and export this data back to 2016. Upgrade now.

Date	Value
December 31, 2023	176.54M
September 30, 2023	129.29M
June 30, 2023	100.84M
March 31, 2023	142.25M
December 31, 2022	89.14M
September 30, 2022	39.69M
June 30, 2022	45.69M
March 31, 2022	49.26M
December 31, 2021	75.80M
September 30, 2021	111.90M
June 30, 2021	49.47M
March 31, 2021	-185.22M
December 31, 2020	-278.92M
September 30, 2020	-262.85M
June 30, 2020	-200.22M
March 31, 2020	5.342M

Date	Value
December 31, 2019	94.94M
September 30, 2019	18.85M
June 30, 2019	-15.25M
March 31, 2019	-13.44M
December 31, 2018	-17.46M
September 30, 2018	-5.057M
June 30, 2018	3.752M
March 31, 2018	-89.80M
December 31, 2017	-126.08M
September 30, 2017	-69.11M
June 30, 2017	-73.12M
March 31, 2017	5.682M
December 31, 2016	17.76M
September 30, 2016	-9.066M
June 30, 2016	-40.99M
March 31, 2016	-47.13M

Cash From Investing Definition

Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.

Read full definition.

Cash from Investing (TTM) Range, Past 5 Years

-278.92M

Minimum

Dec 2020

176.54M

Maximum

Dec 2023

9.818M

Average

49.26M

Median

Mar 2022

Cash from Investing (TTM) Benchmarks